What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Eli Lilly sells two medicines it describes in the U.S. as weight-management products: injectable Zepbound (tirzepatide) and oral Foundayo (orforglipron). Its closely watched candidate retatrutide has reported positive Phase 3 results but remains investigational and limited to clinical-trial participants. Lilly’s latest reported quarterly revenue—$23.0 billion in Q2 2026—was company-wide, not a disclosed total for its weight-loss drugs.
What weight-loss drugs does Eli Lilly make?
As of October 4, 2026, Lilly’s U.S. portfolio includes two marketed medicines described for chronic weight management. Mounjaro also contains tirzepatide, the same active ingredient as Zepbound, but Lilly describes Mounjaro as a type 2 diabetes medicine, not as a substitute label for Zepbound’s weight-management indication.
| Medicine | Format and status in the U.S. | Indication or development status described by Lilly |
|---|---|---|
| Zepbound (tirzepatide) | Prescription injection; marketed | For adults with obesity, or some adults with overweight and a weight-related medical problem, alongside reduced-calorie eating and increased physical activity. Lilly also describes a U.S. indication for adults with obesity and moderate-to-severe obstructive sleep apnea. |
| Foundayo (orforglipron) | Once-daily oral medicine; marketed | For adults with obesity, or some adults with overweight and a weight-related medical problem. Lilly describes it as a small-molecule, non-peptide GLP-1 receptor agonist. |
| Mounjaro (tirzepatide) | Marketed diabetes medicine | Lilly describes it for improving blood glucose in adults and children aged 10 and older with type 2 diabetes, alongside diet and exercise. In August 2026, Lilly announced U.S. FDA approval to reduce major adverse cardiovascular-event risk in adults with type 2 diabetes at high risk. |
| Retatrutide | Investigational; trial-only | Once-weekly candidate that activates GIP, GLP-1 and glucagon receptors. Lilly says it is legally available only to clinical-trial participants. |
| Eloralintide and eloraTZP | Investigational pipeline | Lilly describes eloralintide as an amylin-receptor agonist with Phase 3 obesity studies ongoing, and eloraTZP as an investigational combination with tirzepatide. |
Indications and availability can differ by country. The descriptions above are U.S.-centered and reflect Lilly product and company announcements; check the applicable local prescribing information for current, jurisdiction-specific terms. Foundayo’s exact use directions are label-sensitive and should be confirmed in its current prescribing information.
How much money does Lilly make from Mounjaro and Zepbound?
Lilly’s August 5, 2026 Q2 results reported $23.0 billion in total company revenue, up 48% year over year. Lilly said growth was driven primarily by volume increases for Mounjaro and Zepbound. Across the company, volume rose 60% while realized prices fell 13%; those figures describe Lilly’s overall results, not the two products individually. The company also reported $15.7 billion for its broader “Key Products” group, which includes medicines beyond weight management and is not an obesity-drug sales figure.
Free tools Windows power users keep installed
One-click scans. No signup required.
#1 Best Overall
The Q2 release did not establish a combined revenue total for Zepbound and Mounjaro, nor does the Mounjaro figure represent weight-loss-drug sales: Mounjaro is described by Lilly as a type 2 diabetes product. Therefore, the reported company-wide or Key Products totals cannot answer how much revenue Lilly makes specifically from weight-loss treatment.
What does Lilly expect for 2026?
With its Q2 results, Lilly raised its full-year 2026 revenue guidance to $85.0 billion–$87.0 billion. This is management’s forecast for the whole company, not a reported outcome or a forecast for weight-loss medicines alone.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
What do retatrutide’s trial results show?
Retatrutide is a prominent part of Lilly’s growth pipeline, but trial results are not evidence that the drug is approved or available by prescription. The reported outcomes below come from Lilly announcements and apply to the particular study populations, doses and time periods—not to every person who might use a future approved medicine.
TRIUMPH-2: participants with type 2 diabetes
In a Phase 3, randomized, double-blind, placebo-controlled study lasting 80 weeks, Lilly reported that participants with obesity or overweight and type 2 diabetes in the 12 mg retatrutide arm lost an average of 49.6 pounds (20.8%). Lilly also reported an average A1C reduction of up to 1.6 percentage points. Lilly announced the results on September 29, 2026, saying they were presented at the European Association for the Study of Diabetes meeting and published in The Lancet. The average is a study result, not a promised individual outcome.
Recommended Free Tools
TRIUMPH-4: participants with knee osteoarthritis
Lilly reported that the 9 mg and 12 mg retatrutide arms met the study’s primary and key secondary endpoints at 68 weeks among people with obesity or overweight and knee osteoarthritis. Its 2025 announcement reported up to 28.7% average weight loss and a 4.5-point reduction in WOMAC pain score; 84.0% of participants began with a BMI of at least 35 kg/m². These company-announced findings concern a selected trial population and do not change retatrutide’s investigational status.
When could retatrutide reach the market?
Lilly said in its Q2 2026 release that its retatrutide Phase 3 data package was complete to support global registration submissions for obesity, obstructive sleep apnea and knee osteoarthritis pain. The company said it planned to submit a U.S. Biologics License Application in Q1 2027. That is Lilly’s stated plan, not an FDA filing confirmation, regulatory acceptance or approval date.
Rank #4
Positive Phase 3 findings do not themselves authorize sale. Until an applicable regulator approves the medicine and Lilly makes it available under the relevant terms, retatrutide remains a clinical-trial candidate. Lilly says it is legally available only to trial participants; purported retail or compounded versions are not a route to an approved Lilly product.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What Lilly’s business figures do—and do not—tell investors
- Demand and price moved in different directions. Lilly attributed growth primarily to Mounjaro and Zepbound volume, while lower realized prices partially offset higher volume. The company-wide 60% volume increase and 13% realized-price decline do not identify either product’s separate contribution.
- Company revenue is not obesity-drug revenue. The $23.0 billion quarterly total and $85.0 billion–$87.0 billion full-year guidance cover Lilly as a whole. The $15.7 billion Key Products group also spans medicines beyond weight management.
- Pipeline potential is not current sales. Retatrutide and eloralintide-related programs may matter to Lilly’s future portfolio, but neither is a marketed weight-loss option in the U.S. as described here.
- Clinical outcomes are not a head-to-head ranking. The cited retatrutide trial results came from different populations and durations. They do not establish comparative superiority over Zepbound, Foundayo, or another medicine.
For personal-finance readers, the key distinction is between a fast-growing company and a separately quantified weight-loss-drug business: Lilly’s Q2 release supports the former and attributes much of the growth to Mounjaro and Zepbound volume, but it does not provide a standalone revenue figure for those products together or for weight management alone.
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
